GPT · OpenAI
Introducing new capabilities to GPT-Rosalind
Compiled by KHAO Editorial — aggregated from 1 source. See llms.txt for citation guidance.
★ Tier-1 Source
Bringing greater intelligence grounded in real scientific workflows for the life sciences industry.
Key facts
- GPT‑Rosalind out-performs GPT‑5.5 at 27.5% vs. 25.1% on MedChemBench, while using 7.2% fewer tokens
- GPT‑Rosalind scores 63.2% vs. GPT‑5.5 at 55.8%, while using 5.3% fewer tokens
- Study open-label Phase 1b/2 in 12 ambulatory boys age 4–7 with confirmed DMD and out-of-frame rod-domain deletions
- On GeneBench, their agentic evaluation on long horizon, end-to-end analysis in genomics and quantitative biology, GPT‑Rosalind uses 31% fewer tokens than GPT‑5.5 while achieving a higher accuracy of 21.6% vs
Summary
They're introducing a new model update to their GPT‑Rosalind series purpose-built for life sciences research at enterprise scale. Progress in life sciences depends on synthesizing data and evidence across scales and modalities: molecules, genes, pathways, and living systems. To measure and continuously improve the real-world impact of GPT‑Rosalind, they designed LifeSciBench, an externally expert-judged benchmark focused on foundational aspects in life sciences research. Extracting, reconciling, and auditing scientific evidence from papers, figures, tables, and experimental records.